{"title":"膀胱癌患者在接受各种抗癌化疗时血小板计数的不同波动模式","authors":"Ayako Watanabe, Yu Ogawa, Misa Saeki, Takuya Nagata, Masashi Morita, Kenji Momo","doi":"10.1159/000541679","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>In general, platelet counts fluctuate in cancer patients receiving anticancer therapy. It may include thrombocytopenia caused by bone marrow suppression due to cytotoxic anticancer agents and thrombocytosis due to rebound during recovery. This should not be the case in the case of administration of immune checkpoint inhibitors, given their mechanism of action.</p><p><strong>Case presentation: </strong>However, we have experienced a case of thrombocytosis in a patient treated with an immune checkpoint inhibitor. We present a platelet count pattern in patient with bladder cancer underwent Gemcitabine and Cisplatin (GC) therapy and pembrolizumab monotherapy.</p><p><strong>Conclusion: </strong>This case underscores the need for a diverse perspective on platelet behavior in clinical settings.</p>","PeriodicalId":9625,"journal":{"name":"Case Reports in Oncology","volume":"17 1","pages":"1277-1281"},"PeriodicalIF":0.7000,"publicationDate":"2024-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11556855/pdf/","citationCount":"0","resultStr":"{\"title\":\"Different Patterns of Platelet Count Fluctuation in Response to Various Anticancer Chemotherapies among Patient with Bladder Cancer.\",\"authors\":\"Ayako Watanabe, Yu Ogawa, Misa Saeki, Takuya Nagata, Masashi Morita, Kenji Momo\",\"doi\":\"10.1159/000541679\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>In general, platelet counts fluctuate in cancer patients receiving anticancer therapy. It may include thrombocytopenia caused by bone marrow suppression due to cytotoxic anticancer agents and thrombocytosis due to rebound during recovery. This should not be the case in the case of administration of immune checkpoint inhibitors, given their mechanism of action.</p><p><strong>Case presentation: </strong>However, we have experienced a case of thrombocytosis in a patient treated with an immune checkpoint inhibitor. We present a platelet count pattern in patient with bladder cancer underwent Gemcitabine and Cisplatin (GC) therapy and pembrolizumab monotherapy.</p><p><strong>Conclusion: </strong>This case underscores the need for a diverse perspective on platelet behavior in clinical settings.</p>\",\"PeriodicalId\":9625,\"journal\":{\"name\":\"Case Reports in Oncology\",\"volume\":\"17 1\",\"pages\":\"1277-1281\"},\"PeriodicalIF\":0.7000,\"publicationDate\":\"2024-11-12\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11556855/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Case Reports in Oncology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1159/000541679\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q4\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Case Reports in Oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1159/000541679","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
Different Patterns of Platelet Count Fluctuation in Response to Various Anticancer Chemotherapies among Patient with Bladder Cancer.
Introduction: In general, platelet counts fluctuate in cancer patients receiving anticancer therapy. It may include thrombocytopenia caused by bone marrow suppression due to cytotoxic anticancer agents and thrombocytosis due to rebound during recovery. This should not be the case in the case of administration of immune checkpoint inhibitors, given their mechanism of action.
Case presentation: However, we have experienced a case of thrombocytosis in a patient treated with an immune checkpoint inhibitor. We present a platelet count pattern in patient with bladder cancer underwent Gemcitabine and Cisplatin (GC) therapy and pembrolizumab monotherapy.
Conclusion: This case underscores the need for a diverse perspective on platelet behavior in clinical settings.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
